<DOC>
	<DOCNO>NCT02922179</DOCNO>
	<brief_summary>Over past 40 year , new type insulin market mirror effect endogenous insulin . With exist long-acting insulin product patent expire FDA approval new biosimilar innovator insulin , adult diabetes physicians additional therapeutic option . This observational study describe patient characteristic new exist user long-acting intermediate acting insulin without oral anti-diabetic agent ( OAD ) well acute hypoglycemic episode , acute cardiac event , A1C measure . The Biologic Biosimilars Collective Intelligence Consortium ( BBCIC ) use finding descriptive analysis design comparative study evaluate real-world effectiveness safety biosimilar innovator insulin .</brief_summary>
	<brief_title>Descriptive Analysis Long- Intermediate-Acting Insulin Adult Diabetics</brief_title>
	<detailed_description>Additional information : This protocol design descriptive analysis , support hypothesis . This information provide public interest transparency demonstrate BBCIC 's Distributed Research Network 's ( DRN ) ability define exposure , outcome , covariates confounders . When publish , report caution protocol support ability compare safety effectiveness instead use explore feasibility future , detailed comparative analysis well understand capability BBCIC project . Further , report caution information protocol affect use medical product describe way fact BBCIC perform descriptive analysis way suggest safety effectiveness issue product describe .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Individuals baseline period 183 day continuous medical pharmacy coverage precede first prescription fill new current user follow exposure Longacting insulin ( insulin detemir , glargine ) alone metformin ( LAI ) Longacting insulin ( insulin detemir , glargine ) plus rapid/short act insulin ( without metformin ) ( LAI+R ) Longacting insulin ( insulin detemir , glargine ) plus secondgeneration sulfonylurea agent ( Glimepiride , Glipizide , Glipizide/Metformin , Glyburide , Glyburide/Metformin ) ( without metformin ) ( LAI+sulfa ) NPH insulin ( Humulin , Novolin ) alone metformin ( NPH ) NPH insulin ( Humulin , Novolin ) plus rapid/short act insulin ( without metformin ) ( NHP+R ) NPH insulin ( Humulin , Novolin ) plus secondgeneration sulfonylurea agent ( Glimepiride , Glipizide , Glipizide/Metformin , Glyburide , Glyburide/Metformin ( without metformin ) ( NPH + sulfa ) Adult patient diabetes health insurance evidence insulin pump and/ insulin pump supply , gestational diabetes , liver disorder , dialysis , endstage renal disease ( ESRD ) , amputation , hemoglobinopathy , hemolytic anemia , sickle cell anemia transfusion Emergency Department ( ED ) visit hypoglycemia ; hospitalization ED visit cardiovascular event ( stroke , acute myocardial infarction , unstable angina diagnosis consistent unstable angina i.e. , occlusion without infarction coronary insufficiency ) . Adult patient diabetes insulin except cohort insulin ( i.e. , rapid/short unless combination ) . * Adult patient diabetes firstgeneration sulfonylurea , Dipeptidyl peptidase4 ( DPP4 ) , Glucagonlike Peptide ( GLP ) , Sodiumglucose cotransporter2 ( SGLT2 ) Thiazolidinediones ( TZD ) agent , alone combination cohort define drugs* : First generation sulfonylurea agent ( chlorpropamide , tolazamide ) TZDs ( pioglitazone , pioglitazone/metformin , rosiglitazone , rosiglitazone/metformin DPP4s ( sitagliptin , saxagliptin , linagliptin , alogliptin ) GLP1 ( exenatide , liraglutide , dulaglutide ) SGLT2 ( empagliflozin , canagliflozin , dapagliflozin )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Insulin</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Biologic Biosimilars Collective Intelligence Consortium</keyword>
	<keyword>BBCIC</keyword>
	<keyword>Descriptive analysis</keyword>
</DOC>